Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

This study (SENTRY-CD19) tests a gene therapy approach for treating certain blood cancers — specifically leukemias and lymphomas that carry a protein called CD19 — that have come back or stopped responding to other treatments. The therapy uses a modified virus to deliver a new gene into the patient's own blood stem cells, causing them to produce cancer-fighting immune cells (CAR-T cells) inside the body itself, potentially providing a longer-lasting effect than standard CAR-T infusions. **You may be eligible if...** - You are 13 to 90 years old (age 18+ for the first part of the study) - You have CD19-positive leukemia or lymphoma that has relapsed or is refractory - Your heart, lung, liver, and kidney function meet minimum thresholds - Your blood counts are within the required range - You do not have high levels of antibodies to the specific viral vector used **You may NOT be eligible if...** - You have significantly elevated liver enzymes (indicating liver damage) - You have a history of a blood clotting disorder (thrombotic microangiopathy) or cardiomyopathy - You are pregnant or breastfeeding - You have active Graft versus Host Disease - You have a history of severe reactions to corticosteroids - Your most recent chemotherapy was too recent (per protocol timelines) Talk to your doctor to see if this trial is right for you.